Minimal Residual Disease,Acute Leukemia, Hypomethylating Agents, Donor Lymphocyte Infusion, Allogeneic Hematopoietic Cell Transplantation
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCT (NCT03662087) | Nanfang Hospital, Southern Medical University | 2018-10-01 |
Track Minimal Residual Disease,Acute Leukemia, Hypomethylating Agents, Donor Lymphocyte Infusion, Allogeneic Hematopoietic Cell Transplantation automatically
Every clearance here is in the API, with alerts when new ones post.